ArticleScientific reports2025
Repurposing SARS CoV 2 ligands identifies salvianolic acid C as potential antiviral candidate against human metapneumovirus through computational study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Metapneumovirus (HMPV) is a leading cause of respiratory tract infections worldwide, with no approved antiviral treatments or vaccines currently available. This study explores the potential of repurposing SARS-CoV-2 ligands as therapeutic agents against HMPV through a comprehensive computational approach. The present study investigates three ligands, Salvianolic Acid C, Mycophenolic Acid, and Aurintricarboxylic Acid for their binding affinity, stability, and interaction dynamics with the HMPV protein structure using molecular docking, molecular dynamics (MD) simulations, binding free energy calculations, and principal component analysis (PCA). The results revealed that Salvianolic Acid C formed the most stable complex with HMPV protein model, exhibiting consistent RMSD values (5-6 Å), low residual fluctuations, and a favorable binding free energy of -26.12 kcal/mol. Hydrogen bond analysis further supported its stability, with a 20.97% occupancy between GLU96 of HMPV protein model and Salvianolic Acid C. In contrast, Mycophenolic Acid and Aurintricarboxylic Acid demonstrated weaker binding and higher conformational heterogeneity. PCA and free energy landscape (FEL) analysis confirmed the stable binding mode of Salvianolic Acid C, with well-defined, deep energy basins, while the other ligands exhibited fragmented and less stable conformations. Furthermore, these findings highlight that Salvianolic Acid C as a promising candidate for anti-HMPV therapy, leveraging its stable binding and favorable thermodynamic properties. This study provides a foundation for the development of targeted antiviral treatments against HMPV protein model, addressing a critical unmet need in respiratory disease management for further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.